Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Gain Therapeutics receives Australian HREC approval to begin phase I study of GT-02287 for GBA1-Parkinson’s disease
BioWorld
Related Posts
Post navigation
Previous Post
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
Next Post
FORCE Family Office Webinar
Latest Articles
Clear Filters
March 14, 2023
Oppenheimer 33rd Annual Healthcare Conference
Read More
May 16, 2022
Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update
Read More
September 12, 2023
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
Read More
Close
